BiTE-ing into prostate cancer with bispecific T cell engagers.
2021
Targeting prostate-specific membrane antigen (PSMA) has important therapeutic ramifications, more recently including immune oncology. Data were recently presented on the preclinical efficacy of a half-life extended bispecific T cell engager, AMG 160, which binds PSMA and CD3 to induce T cell-driven cytolytic activity against prostate cancer.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
6
References
0
Citations
NaN
KQI